摘要
原发性肝癌多数患者就诊时已属晚期,生存期短,预后极差,严重威胁我国人民的生命和健康。近年来,肝细胞癌的系统治疗取得了突破进展,特别是以免疫检查点抑制剂为代表的免疫治疗,打破了分子靶向药物的单一治疗局面,而免疫联合抗血管生成靶向治疗策略更显示出优效性,深刻改变了肝癌围手术期的治疗格局。本文重点探讨免疫检查点抑制剂联合抗血管生成靶向药物在肝癌围手术期应用场景的几个热点问题,并就免疫联合靶向药物治疗方案在肝癌围手术期应用的最新研究进展进行盘点。
Most patients with primary hepatocellular carcinoma(HCC)are already in advanced stage when they are diagnosed,with a short survival period and an extremely poor prognosis.HCC seriously threatens the life and health of Chinese people.In recent years,breakthroughs have been made in systemic treatment of HCC,especially in immunotherapy represented by immune checkpoint inhibitors,which has broken the single therapy situation of molecular targeted drugs.And the strategy of immunotherapy combined with anti-angiogenic therapy has shown superiority and profoundly changed the treatment strategy of HCC.This article focuses on several hotspots of immune checkpoint inhibitors combined with anti-angiogenic targeted drugs in the perioperative scenario of HCC,and takes stock of the latest research progress of immunotherapy combined with anti-angiogenic drugs regimens in the perioperative application of HCC.
作者
卢实春
高彪
王亚飞
Lu Shichun;Gao Biao;Wang Yafei(Faculty of Hepato-Pancreato-Biliary Surgery,Chinese PLA General Hospital,Institute of Hepatobiliary Surgery of Chinese PLA,Key Laboratory of Digital Hepatobiliary Surgery PLA,Beijing 100853,China)
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2023年第1期1-4,共4页
Chinese Journal of Hepatobiliary Surgery
关键词
癌
肝细胞
肿瘤辅助疗法
免疫联合治疗
转化治疗
系统治疗
Carcinoma,hepatocellular
Neoadjuvant therapy
Immune combination therapy
Conversion therapy
Systemic therapy
